Immuneering Corp IMRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:17 PM EDT
1.53quote price arrow down-0.04 (-2.66%)
Volume
84,921
52 week range
1.38 - 11.92
Loading...
  • Open1.56
  • Day High1.64
  • Day Low1.50
  • Prev Close1.57
  • 52 Week High11.92
  • 52 Week High Date06/21/23
  • 52 Week Low1.38
  • 52 Week Low Date05/01/24

Key Stats

  • Market Cap45.319M
  • Shares Out29.65M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta-0.6
  • YTD % Change-79.05

KEY STATS

  • Open1.56
  • Day High1.64
  • Day Low1.50
  • Prev Close1.57
  • 52 Week High11.92
  • 52 Week High Date06/21/23
  • 52 Week Low1.38
  • 52 Week Low Date05/01/24
  • Market Cap45.319M
  • Shares Out29.65M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta-0.6
  • YTD % Change-79.05

RATIOS/PROFITABILITY

  • EPS (TTM)-1.86
  • P/E (TTM)-0.82
  • Fwd P/E (NTM)-0.75
  • EBITDA (TTM)-58.693M
  • ROE (TTM)-61.38%
  • Revenue (TTM)-
  • Gross Margin (TTM)100.00%
  • Net Margin (TTM)-11,224,720.00%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/18/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Immuneering Corp

 

Profile

MORE
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The...
Robert Carpenter
Independent Chairman of the Board, Co-Founder
Benjamin Zeskind Ph.D.
President, Chief Executive Officer, Co-Founder, Director
Mallory Morales
Principal Financial Officer, Principal Accounting Officer
Michael Bookman
General Counsel, Secretary, Chief Legal Officer
Address
245 Main St Fl 2
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
XLO
Xilio Therapeutics Inc
1.11-0.01-0.89%
TCRT
Alaunos Therapeutics Inc
1.15-0.04-3.30%
MTNB
Matinas BioPharma Holdings Inc
0.174+0.0014+0.8111%
INAB
IN8BIO, Inc.
1.01-0.12-10.62%
TIL
Instil Bio Inc
11.65-0.45-3.72%